This document is an evidence-based summary to complement treatment protocols and includes background and rationale for specific point of care actions. It is not intended to be a comprehensive literature review of all available evidence.

Please note this document refers only to the management of treatment induced diarrhoea. It does not cover the management of gastrointestinal graft-versus-host disease (GVHD). 
This document should NOT be used for the management of PD-1 (eg. nivolumab and pembrolizumab), PD-L1 (eg. atezolizumab, avelumab and durvalumab) or CTLA-4 (eg. ipilimumab) inhibitor related diarrhoea – please refer to Management of immune related adverse events (irAEs) document

This document reflects what is currently regarded as safe practice. While every effort has been made to ensure the accuracy of the content at the time of publication, the Cancer Institute NSW does not accept any liability, with respect to loss, damage, injury or expense arising from any such errors or omission in the contents of this work. Any reference throughout the document to specific pharmaceuticals and/or medical products as examples does not imply endorsement of any of these products. While eviQ endeavours to link to reliable sources that provide accurate information, eviQ and the Cancer Institute NSW do not endorse or accept responsibility for the accuracy, currency, reliability or correctness of the content of linked external information source. Use is subject to eviQ’s disclaimer available at

Send feedback for this page

First approved:
Last reviewed:
Review due:

The currency of this information is guaranteed only up until the date of printing, for any updates please check:

14 Jul 2024